Ndukaku Ogbonna, MD
Internal Medicine · Omaha, NENPI 1841064086
Payments from drug & device makers
No general payments reported
No drug or device maker reported general payments to this provider for 2019–2025. That is a common and unremarkable result.
How this compares
$0 in reported general payments places this provider in the 10th percentile of 570 internal medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sodium Chloride0.9 % Sodium Chloride | 68 | $4,100 |
| Doxycycline Hyclate | 21 | $3,783 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 25 | $3,112 |
| Meropenem | 11 | $933 |
| Potassium Chloride | 12 | $439 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Omaha
- Michael DunnOmaha$7.9M
- Joel MichalskiOmaha$1.6M
- Ariana BauerOmaha$1.5M
- David CrockettOmaha$821K
- Bryant EnglandOmaha$637K
- Adam BurdorfOmaha$313K
- Brian BoerOmaha$142K
- David JasperOmaha$128K
- Andrew RorieOmaha$61K
- Mohamed AhmedOmaha$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.